Effect of Endocrine Therapy Combined with Trastuzumab Targeted Therapy on Response Rate and Quality of Life in HER2-Positive Metastatic Breast Cancer
Abstract
Objective: To analyze the effect of endocrine therapy combined with trastuzumab targeted therapy on HER2 (human epidermal growth factor receptor-2) positive metastatic breast cancer on the treatment efficiency and quality of life. Methods: Selected 100 patients with HER2-positive metastatic breast cancer who were treated in our hospital from January 2019 to December 2021, and divided them into a control group and an observation group according to the random number table method, with 50 cases in each group, and were given the clinical effects of single trastuzumab targeted therapy and endocrine therapy combined with trastuzumab targeted therapy were compared. Results: There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05); the remission rate in the observation group was significantly higher than that in the control group (P<0.05); the overall health scale and function scale scores in the observation group were higher than those in the control group, and the individual items Measurement and symptom scale scores were lower than those in the control group (P < 0.05). Conclusion: Endocrine therapy combined with trastuzumab targeted therapy for HER2-positive metastatic breast cancer can effectively relieve the patient's condition and improve the patient's quality of life. The clinical effect is significant, and it is worthy of widespread application.
References
[2] Shi EJ, Wu QR. Clinical Efficacy and Safety of Chemotherapy Combined with Trastuzumab in the Treatment of Human Epidermal Growth Factor Receptor 2-positive Metastatic Breast Cancer [J]. Medical Equipment, 2021, 34(7) :91-92.
[3] Wang QQ, Luo X, Dang HF, et al. Pyrotinib + Trastuzumab + Chemotherapy for a Case of Advanced HER-2 Positive Breast Cancer [J]. Gansu Medicine, 2021, 40(11) :1049-1050,1052.
[4] National Cancer Center for Quality Control Breast Cancer Expert Committee, China Anti-Cancer Association Cancer Drug Clinical Research Professional Committee. Consensus on the Clinical Application of CDK4/6 Inhibitors in the Treatment of Hormone Receptor-positive Human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer [J]. Chinese Journal of Oncology, 2021, 43(4): 405-413.
[5] Yi ZB. Interpretation of Endocrine Therapy and Targeted Therapy in Patients with HR+/HER2- Metastatic Breast Cancer: ASCO Updated Guidelines [J]. Electronic Journal of Comprehensive Cancer Therapy, 2021,7(4):37-42.
[6] Zhang YQ, Sun LZ, Wang YF, et al. Clinical Observation of Trastuzumab Combined with Endocrine Maintenance in the Treatment of HR and HER-2 Positive Advanced Breast Cancer [J]. Journal of Clinical Oncology, 2017, 22(5): 427 -431.
Copyright (c) 2022 Xulong Zhu, Feifei Zhang, Jian Jiao, Hongyi Zhang, Binliang Huo
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors submitting to USP journals agree to publish their manuscript under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0) where authors agree to allow third parties to share their work (copy, distribute, transmit) and to adapt it, under the condition that the authors are given credit, and that in the event of reuse or distribution, the terms of this license are made clear
Authors retain copyright of their work, with first publication rights (online and print) granted to Universe Scientific Publishing or the owner of the journal in question.
